Responsiveness and non-responsiveness to transfused RBCs in mice and humans.
小鼠和人类对输注红细胞的反应性和无反应性。
基本信息
- 批准号:9918440
- 负责人:
- 金额:$ 41.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAdoptive TransferAlloimmunizationAnimalsAntibodiesAntibody FormationAntigen-Presenting CellsAntigensBioinformaticsBiologicalBlood Group AntigensBlood donorCD4 Positive T LymphocytesCaringCellsCollaborationsConsumptionDangerousnessDevelopmentEnvironmental Risk FactorErythrocyte TransfusionErythrocytesEvaluationEventExposure toFetal ErythroblastosisGYPA geneGenerationsGenesGeneticGenomicsGlycoproteinsGoalsGrantHelper-Inducer T-LymphocyteHumanImmunologicsImmunologistInflammationInflammatoryInterferon ReceptorInterferonsInvestigationIsoantibodiesKnowledgeLaboratoriesMediatingMinorityModelingMusNatural ImmunityOutcomePathway interactionsPatientsPatternPhenotypePilot ProjectsPopulationProcessProductionPublic HealthPublishingReactionReporterRiskRoleRouteSafetySickle Cell AnemiaSignal PathwaySignal TransductionT-Lymphocyte SubsetsTestingTherapeutic InterventionTimeTranscendTransfusionadaptive immunitycell typeclinically significantdifferential expressionhazardimmune activationimprovedin vivoinsightmouse modelnovelpreventreceptorresponders and non-respondersresponsescreeningtranscriptometranscriptome sequencing
项目摘要
Background: It remains unclear why certain transfusion recipients make clinically significant RBC alloantibody
after antibody (“responders”), yet others are transfused hundreds of times without generating any detectable
alloantibodies (“non-responders”). We have discovered that the recipient inflammatory status at the time of
RBC transfusion, in combination with the ability of the recipients to sense type 1 interferons (IFN), are critical in
determining responder/non-responder status in our reductionist murine models. Further, recent studies in
humans suggest that the inflammation/alloimmunization connection transcends mice, though genetic variables
must also be considered.
Central Hypothesis: We hypothesize that inflammation (specifically type 1 IFN induction and sensing) and
genetic factors together determine which transfusion recipients will form alloantibodies following RBC
transfusion, with non-responders possibly being tolerant and not simply ignorant of RBC antigens. The
proposed studies utilize reductionist murine models, with blood donors expressing the authentic human blood
group antigens glycophorin A (hGPA) or KEL glycoprotein, and with genetically identical recipients generating
RBC alloantibodies only when transfusion occurs in the presence of an adjuvant or an ability to sense IFNs. In
depth in vivo studies of early immune activation events in responder and non-responder mice, in combination
with ex vivo studies of CD4+ T-cell subset phenotype, function, and transcriptome in responder and non-
responder humans, seek to increase knowledge of RBC alloimmunization.
Specific Aim 1: To investigate which recipient cell population(s) in mice mediate responsiveness to
transfused RBCs.
Specific Aim 2: To investigate the mechanism(s) through which non-responsiveness in mice occurs
following transfusion.
Specific Aim 3: To investigate differences in CD4+ T-cells in responder and non-responder humans.
背景:某些输血受者产生具有临床意义的红细胞同种异体抗体的原因尚不清楚。
在抗体(“响应者”)之后,还有其他抗体被输注数百次,但没有产生任何可检测到的
同种异体抗体(“无反应者”)。我们发现受者在接受治疗时的炎症状态
RBC输注,结合受者感知1型干扰素的能力,在
在我们的简化论小鼠模型中确定应答者/非应答者状态。此外,最近对
人类认为,炎症/同种异体免疫之间的联系超越了老鼠,尽管存在遗传变量
也必须考虑。
中心假设:我们假设炎症(特别是1型干扰素的诱导和感觉)和
遗传因素共同决定了哪些输血者会在RBC后形成同种异体抗体
输血,无应答者可能会有耐受性,而不仅仅是对红细胞抗原一无所知。这个
建议的研究利用简化的小鼠模型,献血者表达真实的人类血液
组抗原血糖素A(HGPA)或Kel糖蛋白,并与遗传相同的受体产生
只有当输血时有佐剂存在或有能力感知干扰素时,才能产生红细胞同种抗体。在……里面
对应答和无应答小鼠早期免疫激活事件的联合体内深入研究
应答者和非应答者的CD4+T细胞亚群表型、功能和转录组的体外研究
响应人类,寻求增加关于红细胞同种异体免疫的知识。
特定目的1:研究小鼠体内的哪种受体细胞群(S)介导对
输注的红细胞。
特定目的2:探讨小鼠无反应性发生的机制(S)
在输血后。
具体目标3:研究应答者和无应答者的CD4+T细胞的差异。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PATRICK G GALLAGHER其他文献
PATRICK G GALLAGHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PATRICK G GALLAGHER', 18)}}的其他基金
Novel Mechanisms of Congenital Dyserythropoietic Anemia
先天性红细胞生成不良性贫血的新机制
- 批准号:
10454333 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
Novel Mechanisms of Congenital Dyserythropoietic Anemia
先天性红细胞生成不良性贫血的新机制
- 批准号:
9887377 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
Novel Mechanisms of Congenital Dyserythropoietic Anemia
先天性红细胞生成不良性贫血的新机制
- 批准号:
10192709 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
Nonenzymatic Gene Editing in Treatment of Heredity Spherocytosis
非酶基因编辑治疗遗传性球形红细胞增多症
- 批准号:
10305603 - 财政年份:2019
- 资助金额:
$ 41.88万 - 项目类别:
Coordinated regulation of vascular smooth muscle phenotype by p300, CBP, and TET2
p300、CBP 和 TET2 对血管平滑肌表型的协调调节
- 批准号:
10308706 - 财政年份:2018
- 资助金额:
$ 41.88万 - 项目类别:
Yale Cooperative Center of Excellence in Hematology
耶鲁大学血液学卓越合作中心
- 批准号:
10454355 - 财政年份:2015
- 资助金额:
$ 41.88万 - 项目类别:
Yale Cooperative Hematology Specialized Core Center
耶鲁大学合作血液学专业核心中心
- 批准号:
9987207 - 财政年份:2015
- 资助金额:
$ 41.88万 - 项目类别:
Yale Cooperative Center of Excellence in Hematology
耶鲁大学血液学卓越合作中心
- 批准号:
10249339 - 财政年份:2015
- 资助金额:
$ 41.88万 - 项目类别:
Yale Cooperative Hematology Specialized Core Center
耶鲁大学合作血液学专业核心中心
- 批准号:
8972977 - 财政年份:2015
- 资助金额:
$ 41.88万 - 项目类别:
Yale Cooperative Hematology Specialized Core Center
耶鲁大学合作血液学专业核心中心
- 批准号:
9325318 - 财政年份:2015
- 资助金额:
$ 41.88万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 41.88万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 41.88万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 41.88万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 41.88万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 41.88万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 41.88万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 41.88万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 41.88万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 41.88万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 41.88万 - 项目类别: